High throughput screens yield small molecule inhibitors of leishmania CRK3:CYC6 cyclin-dependent kinase

PLoS Neglected Tropical Diseases

Volumn 5, Issue 4, 2011, Pages

  Walker, Roderick G ^a   Thomson, Graeme ^b   Malone, Kirk ^c   Nowicki, Matthew W ^d   Brown, Elaine ^a   Blake, David G ^b   Turner, Nicholas J ^c   Walkinshaw, Malcolm D ^d   Grant, Karen M ^e   Mottram, Jeremy C ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b CYCLACEL LTD   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

^e LANCASTER UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZAPURINE DERIVATIVE; CYCLIN A; CYCLIN C6; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 2 RELATED KINASE 3; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLINE; PROTEIN SERINE THREONINE KINASE; PURINE DERIVATIVE; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; ANTIPROTOZOAL AGENT; CYCLIN DEPENDENT KINASE; PROTEIN KINASE INHIBITOR;

AMASTIGOTE; ANTIPROTOZOAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG SYNTHESIS; DRUG TARGETING; ENZYME INHIBITION; ENZYME SPECIFICITY; FLUORESCENCE POLARIZATION IMMUNOASSAY; HIGH THROUGHPUT SCREENING; LEISHMANIA; NONHUMAN; PHARMACOPHORE; PROMASTIGOTE; PROTEIN EXPRESSION; PROTEIN PURIFICATION; STRUCTURE ACTIVITY RELATION; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; DRUG SENSITIVITY; HUMAN; ISOLATION AND PURIFICATION; LEISHMANIA MAJOR; METHODOLOGY; MOUSE;

ANIMALS; ANTIPROTOZOAL AGENTS; CYCLIN-DEPENDENT KINASES; DRUG EVALUATION, PRECLINICAL; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LEISHMANIA MAJOR; MICE; MICE, INBRED BALB C; PARASITIC SENSITIVITY TESTS; PROTEIN KINASE INHIBITORS;

EID: 79955870371     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001033     Document Type: Article

References (39)

1. Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, et al. (2007) Cutaneous leishmaniasis. Lancet 7: 581-596.
2. Croft SL, Sundar S, Fairlamb AH, (2006) Drug resistance in leishmaniasis. Clin Microbiol Rev 19: 111-126.
3. Croft SL, Coombs GH, (2003) Leishmaniasis-current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol 19: 502-508.
4. Naula C, Parsons M, Mottram JC, (2005) Protein kinases as drug targets in trypanosomes and Leishmania. Biochimica et Biophysica Acta: Proteins and proteomics 1754: 151-159.
5. Grant KM, (2008) Targeting the cell cycle in the pursuit of novel chemotherapies against parasitic protozoa. Curr Pharm Des 14: 917-924.
6. Zhang J, Yang PL, Gray NS, (2009) Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 9: 28-39.
7. Cohen P, (2009) Targeting protein kinases for the development of anti-inflammatory drugs. Curr Opin Cell Biol 21: 317-324.
8. Cohen P, (2002) Protein kinases-the major drug targets of the twenty-first century? Nat Rev Drug Discov 1: 309-315.
9. Malumbres M, Barbacid M, (2005) Mammalian cyclin-dependent kinases. Trends Biochem Sci 30: 630-641.
10. Senderowicz AM, (1999) Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials. Invest New Drugs 17: 313-320.
11. Fischer PM, (2004) The use of CDK inhibitors in oncology: a pharmaceutical perspective. Cell Cycle 3: 742-746.
12. Fischer PM, Gianella-Borradori A, (2005) Recent progress in the discovery and development of cyclin-dependent kinase inhibitors. Expert Opin Investig Drugs 14: 457-477.
13. Rosania GR, Chang YT, (2000) Targeting hyperproliferative disorders with cyclin dependent kinase inhibitors. Expert Opin Ther Pat 10: 215-230.
14. Shapiro GI, (2004) Preclinical and clinical development of the cyclin-dependent kinase inhibitor Flavopiridol. Clin Cancer Res 10: 4270S-44275.
15. McClue SJ, Blake D, Clarke R, Cowan A, Cummings L, et al. (2002) In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer 102: 463-468.
16. Grant KM, Hassan P, Anderson JS, Mottram JC, (1998) The crk3 gene of Leishmania mexicana encodes a stage-regulated cdc2-related histone H1 kinase that associates with p12cks1. J Biol Chem 273: 10153-10159.
17. Tu X, Wang CC, (2004) The involvement of two cdc2-related kinases (CRKs) in Trypanosoma brucei cell-cycle regulation and the distinctive stage-specific phenotypes caused by CRK3 depletion. J Biol Chem 279: 20519-20528.
18. Hammarton TC, Mottram JC, Doerig CD, (2003) The cell cycle of parasitic protozoa: potential for chemotherapeutic exploitation. Prog Cell Cycle Res 5: 91-101.
19. Wang YX, Dimitrov K, Garrity LK, Sazer S, Beverley SM, (1998) Stage-specific activity of the Leishmania major CRK3 kinase and functional rescue of a Schizosaccharomyces pombe cdc2 mutant. Mol Biochem Parasitol 96: 139-150.
20. Hassan P, Fergusson D, Grant KM, Mottram JC, (2001) The CRK3 protein kinase is essential for cell cycle progression of Leishmania mexicana. Mol Biochem Parasitol 113: 189-198.
21. Liu Y, Gray NS, (2006) Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol 2: 358-364.
22. Lipinski CA, (2000) Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 44: 235-249.
23. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ, (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46: 3-26.
24. Chin YW, Balunas MJ, Chai HB, Kinghorn AD, (2006) Drug discovery from natural sources. AAPS J 8: E239-E253.
25. Sali A, Blundell TL, (1993) Comparative Protein Modelling by Satisfaction of Spatial Restraints. J Mol Biol 234: 779-815.
26. Schuttelkopf AW, van Aalten DM, (2004) PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr D Biol Crystallogr 60: 1355-1363.
27. Raz B, Iten M, Grether-Buhler Y, Kaminsky R, Brun R, (1997) The Alamar Blue assay to determine drug sensitivity of African trypanosomes (T.b. rhodesiense and T.b. gambiense) in vitro. Acta Trop 68: 139-147.
28. Eschenlauer SC, Faria MS, Morrison LS, Bland N, Ribeiro-Gomes FL, et al. (2009) Influence of parasite encoded inhibitors of serine peptidases in early infection of macropages with Leishmania major. Cell Microbiol 11: 106-120.
29. Gomes FC, Ali NO, Brown E, Walker RG, Grant KM, et al. (2010) Recombinant Leishmania mexicana CRK3:CYCA has protein kinase activity in the absence of phosphorylation on the T-loop residue Thr178. Mol Biochem Parasitol 171: 89-96.
30. Espinoza FH, Farrell A, Erdjument-Bromage H, Tempst P, Morgan DO, (1996) A cyclin-dependent kinase-activating kinase (CAK) in budding yeast unrelated to vertebrate CAK. Science 273: 1714-1717.
31. Kaldis P, Sutton A, Solomon MJ, (1996) The Cdk-activating kinase (CAK) from budding yeast. Cell 86: 553-564.
32. Thuret JY, Valay JG, Faye G, Mann C, (1996) Civ1 (CAK in vivo), a novel Cdk-activating kinase. Cell 86: 565-576.
33. Morgan DO, (1995) Principles of CDK regulation. Nature 374: 131-134.
34. Zhang JH, Chung TDY, Oldenburg KR, (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 4: 67-73.
35. Iversen PW, Eastwood BJ, Sittampalam GS, Cox KL, (2006) A comparison of assay performance measures in screening assays: signal window, Z′ factor, and assay variability ratio. J Biomol Screen 11: 247-252.
36. Stevenson-Lindert LM, Fowler P, Lew J, (2003) Substrate specificity of CDK2-cyclin A- What is optimal? J Biol Chem 278: 50956-50960.
37. Yuhong D, Moulick K, Rodina A, Aguirre J, Felts S, et al. (2007) High throughput screening fluorescence polarization assay for tumor-specific Hsp90. J Biomol Screen 12: 915-924.
38. Grant KM, Dunion MH, Yardley V, Skaltsounis A-L, Marko D, et al. (2004) Inhibitors of Leishmania mexicana CRK3 cyclin-dependent kinase: chemical library screen and antileishmanial activity. Antimicrob Agents Chem 48: 3033-3042.
39. Davies TG, Bentley J, Arris CE, Boyle FT, Curtin NJ, et al. (2002) Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor. Nature Struct Biol 9: 745-749.